ArticleJournal of translational medicine2026
PD-1 H (VISTA) drives immunosuppressive reprogramming of glioma-associated myeloid cells to promote glioma progression.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioma is characterized by a profoundly immunosuppressive tumor microenvironment (TME) that severely limits immune checkpoint blockade efficacy. Glioma-associated myeloid cells (GAMs), including resident microglia and infiltrating macrophages, constitute the dominant immune population within gliomas and shape antitumor immune responses. While immune checkpoint pathways have been extensively studied in T lymphocytes, the contribution of myeloid-restricted immune checkpoints to glioma progression remains poorly defined. Programmed death-1 homolog (PD-1 H/VISTA) is an inhibitory immune checkpoint predominantly expressed by myeloid cells, yet its functional role in GAMs has not been systematically investigated.
methodsPD-1 H expression in human glioma was analyzed using immunohistochemistry, bulk transcriptomic datasets, and single-cell RNA sequencing. Associations between PD-1 H expression, immune cell composition, and patient survival were evaluated in clinical cohorts. The functional role of PD-1 H in GAMs was examined using genetically manipulated myeloid cells in vitro and orthotopic glioma mouse models in vivo. Transcriptomic profiling was performed to identify PD-1 H-associated biological pathways. The therapeutic potential of PD-1 H blockade was assessed using monoclonal antibody treatment in glioma-bearing mice.
resultsPD-1 H was highly expressed in human glioma tissues and was predominantly enriched in GAMs. Elevated PD-1 H expression was associated with an immunosuppressive tumor microenvironment characterized by increased infiltration of immunosuppressive myeloid populations, reduced cytotoxic T-cell presence, elevated expression of multiple immune checkpoint molecules, and unfavorable clinical outcomes. Functionally, PD-1 H promoted immunosuppressive myeloid polarization, enhanced malignant behaviors of glioma cells, and suppressed CD8
conclusionsPD-1 H functions as a myeloid-restricted immune checkpoint that drives immunosuppressive reprogramming of glioma-associated myeloid cells, promotes glioma progression, and impairs antitumor T-cell immunity. Targeting PD-1 H represents a promising myeloid-focused immunotherapeutic strategy to overcome immune suppression in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.